A global postmarketing observational safety study to evaluate the safety and tolerability of Fycompa (perampanel) as add-on therapy in epilepsy patients aged > 12 years First published 17/07/2015 Last updated 05/12/2024 EU PAS number:EUPAS10320 Study Finalised